Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6795956 | 0.99 | HSD17B10 (0.65) | HSD17B10SMN1; SMN2UCHL1RAB9ANPC1 | |
| SCHEMBL9609459 | 0.97 | HSD17B10 (0.71) | HSD17B10SMN1; SMN2UCHL1RAB9ANPC1 | |
| SCHEMBL2489313 | 0.97 | HSD17B10 (0.71) | HSD17B10SMN1; SMN2UCHL1RAB9ANPC1 | |
| SCHEMBL8395469 | 0.97 | HSD17B10 (0.71) | HSD17B10SMN1; SMN2UCHL1RAB9ANPC1 | |
| SCHEMBL65491 | 0.93 | HSD17B10 (0.63) | HSD17B10SMN1; SMN2UCHL1RAB9ANPC1 | |
| SCHEMBL65490 | 0.93 | HSD17B10 (0.63) | HSD17B10SMN1; SMN2UCHL1RAB9ANPC1 | |
| SCHEMBL77858 | 0.93 | HSD17B10 (0.63) | HSD17B10SMN1; SMN2UCHL1RAB9ANPC1 | |
| SCHEMBL18358031 | 0.91 | HSD17B10 (0.62) | HSD17B10SMN1; SMN2UCHL1RAB9ANPC1 | |
| SCHEMBL222955 | 0.91 | HSD17B10 (0.62) | HSD17B10SMN1; SMN2UCHL1RAB9ANPC1 | |
| SCHEMBL5898691 | 0.91 | HSD17B10 (0.62) | HSD17B10SMN1; SMN2UCHL1RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6515011-B2 | Anticoagulants | MERCK & CO., INC. | 2003-02-04 | — | — | US | disclosed |
| US-20020119992-A1 | Thrombin inhibitors | MERCK & CO., INC. | 2002-08-29 | — | — | US | disclosed |
| WO-2002050056-A1 | BENZYLAMINE DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119992-A1 | Thrombin inhibitors | SERPINC1, F2, TFPI | HSD17B10 1231/4885SMN1; SMN2 4400/4885UCHL1 3894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.